NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs051180175

Registered date:26/03/2019

Bevacizumab therapy for retinopathy of prematurity

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedIntraocular neovascularization
Date of first enrollment03/08/2016
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Intravitreal bevacizumab injection

Outcome(s)

Primary OutcomeIncidence of retinal detachment after treatment
Secondary OutcomeIncidence of cataract after treatment Timing of retinal photocoagulation after treatment

Key inclusion & exclusion criteria

Age minimum0 year-old
Age maximum12 years-old
GenderBoth
Include criteria1, Patients with diseases in which intraocular neovascular vessels do not disappear or reappeared after conventional therapy such as retinal photocoagulation 2, Retinopathy of prematurity, regardless of treatment, is zone I disease, zone II disease with stage 2+ or 3+, and aggressive posterior retinopathy of prematurity in the international classification 3, From 2 weeks old to 12 years old 4, Written informed consent by parents
Exclude criteria1, Patients with infarct disease, heart failure with poor control, hypertension, renal failure, abnormal blood coagulation ability, gastrointestinal ulcer 2, Patients who need to take other treatment priorities due to poor general condition 3. Patients who judged that neonatal specialists, pediatricians or the researcher are inappropriate as research subjects 4. Patients participating in other studies

Related Information

Contact

Public contact
Name Masayuki Ohnaka
Address 2-5-1 Shinmachi, Hirakata, Osaka Osaka Japan 573-1010
Telephone +81-72-804-0101
E-mail ohnakam@hirakata.kmu.ac.jp
Affiliation Kansai Medical University
Scientific contact
Name Masayuki Ohnaka
Address 2-3-1 Shinmachi, Hirakata, Osaka Osaka Japan 573-1010
Telephone +81-72-804-0101
E-mail ohnakam@hirakata.kmu.ac.jp
Affiliation Kansai Medical University Hospital